Treatment
Sirolimus clinical trials
We’re tracking 104 recruiting studies that include Sirolimus, each written for real people, not researchers, below.
Recruiting studies
- NCT07045194Recruiting
Study of Virtue balloon for coronary stent re-narrowing
This trial tests a special balloon to treat narrowed areas inside a previously placed heart stent. It may help by reopening the artery without adding another stent.
Gainesville, FloridaAges 18 years+ - NCT07616154RecruitingPhase 2
Gene-Matched Family Stem Cell Transplant for Severe Sickle Cell
This trial tests whether a stem cell transplant from a partially gene-matched family member can cure severe sickle cell disease in children and young adults. The transplant uses a new approach that may work even when a perfectly matched sibling isn't available, and it might help patients whose sickle cell is causing serious complications like strokes, organ damage, or frequent pain crises.
Memphis, TennesseeAges Up to 22 years - NCT03214354RecruitingPhase 2
Stem cell transplant for children with sickle cell and ABO mismatch
This trial studies a stem cell transplant approach for children with sickle cell disease, using a sibling donor whose blood type is not compatible. It aims to see if this transplant method can safely reduce serious sickle cell complications.
Calgary, AlbertaAges 1–19 - NCT03587272RecruitingPhase 2
Sibling bone marrow transplant to reduce treatment side effects
This study tests a way to do a bone marrow (stem cell) transplant from an HLA-matched sibling in children with sickle cell disease, aiming to lower the risk of serious side effects. You may be considered if you have certain past sickle complications and your body can safely handle the transplant plan.
Washington D.C., District of ColumbiaAges 2–25 - NCT03952637RecruitingPhase 1/Phase 2
Gene therapy for GM1 disease with IV delivery
This early-stage study tests an IV gene therapy that delivers a working copy of an enzyme gene to help the body make beta-galactosidase in GM1 gangliosidosis. It may help slow or improve disease symptoms and looks closely at safety and how well the treatment works.
Bethesda, MarylandAges 6 months–12 years - NCT03970096RecruitingPhase 2
Reduce graft-versus-host disease after stem cell transplant
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Tampa, FloridaAges 1–60 - NCT04888741RecruitingPhase 2
Trial testing reduced immune T cells before stem cell transplant
This Phase 2 trial looks at a transplant approach that reduces harmful immune cells (T cells) before or during an allogeneic stem cell transplant. It may help lower the risk of transplant complications while still letting the donor immune system fight the blood cancer.
Cardiff, WalesAges 16–70 - NCT04923191Recruiting
Test heart-procedure guidance from scans versus usual care
This study compares two ways of guiding a heart stent procedure: using information from a special angiography scan versus using standard practice. It may help your care team choose the best treatment to improve heart outcomes after stenting.
AalstAges 18 years+ - NCT04959175RecruitingPhase 1/Phase 2
Lower post-transplant drug doses for older or unfit patients
This trial tests whether giving a lower dose of cyclophosphamide after a bone marrow transplant can be safer for older or medically “unfit” patients, while still helping control blood cancers. It is designed for people who can’t tolerate the usual strongest transplant preparation.
Bethesda, MarylandAges 12–85 - NCT05327023RecruitingPhase 1/Phase 2
Donor immune cells after bone marrow transplant for high-risk blood cancers
This trial studies giving donor lymphocyte (immune) infusions after a bone marrow transplant for people with high-risk blood cancers. The goal is to help the immune system better fight the cancer and improve outcomes after transplant.
Bethesda, MarylandAges 12–120 - NCT05414292Recruiting
Testing rapamycin effect on exercise muscle function in older adults
This study looks at how rapamycin (a medication that affects a growth signal in the body) changes muscle responses when older adults do resistance exercise. It may help researchers understand whether this treatment could improve or alter muscle function with aging.
DerbyAges 50–90 - NCT05426252RecruitingPhase 1/Phase 2
Lower-toxicity bone marrow conditioning for high-risk thalassemia
This trial tests a modified, lower-toxicity preparation (conditioning) before a bone marrow transplant in children and teens with high-risk thalassemia. It aims to reduce treatment side effects while still allowing transplant success for people who need a donor.
Toronto, OntarioAges 1–18 - NCT05444452Recruiting
Stent treatment study for blocked heart arteries
This study tests a coronary stent approach for people with significantly blocked heart arteries. It may help by improving blood flow, and it compares treatment in a structured way while monitoring safety and outcomes.
SeoulAges 19 years+ - NCT05463133RecruitingPhase 1/Phase 2
Stem cell transplant for CGD using targeted medications and steroids-free support
This trial tests an intensive stem cell transplant approach for people with chronic granulomatous disease (CGD). The study aims to improve outcomes by preparing the body for a donor stem cell graft and using immune “brakes” to reduce immune problems.
Bethesda, MarylandAges 4–65 - NCT05805605RecruitingPhase 2
Low-intensity stem cell transplant with donor cells and blood-protection
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
Minneapolis, MinnesotaAges Up to 75 years - NCT05908331Recruiting
Balloon treatment test for narrowed stents in heart arteries
This trial tests whether a special drug-coated balloon (“MagicTouch”) can treat re-narrowing inside a previously placed stent. It may help patients whose stent has become blocked again, by improving blood flow and reducing repeat narrowing.
Birmingham, AlabamaAges 18–110 - NCT05949658RecruitingPhase 1
Everolimus rapalog study for healthy adults
This early-phase study tests how a medicine called rapalog affects the body in generally healthy middle-aged adults. It may help researchers understand safety and dosing, but it’s not meant to treat an existing disease.
Madison, WisconsinAges 55–89 - NCT06358638RecruitingPhase 2
Sickle cell transplant using a gentler approach for patients with donor antibodies
This trial is testing a new, gentler type of bone marrow transplant for children and young adults with sickle cell disease who have a healthy sibling donor with a mismatched blood type or who have antibodies against their donor's red blood cells. The goal is to replace the faulty bone marrow with healthy donor cells, with fewer side effects than traditional transplants.
Washington D.C., District of ColumbiaAges 2–25 - NCT06551662Recruiting
Balloon vs. stent for split artery blockages
This trial compares two ways to open a blocked artery that splits into two branches (a bifurcation): using a balloon coated with medicine (drug-coated balloon, or DCB) versus a drug-eluting stent (DES). The goal is to see which approach works better for patients with this type of blockage.
MilanAges 18 years+ - NCT07091682Recruiting
A trial of a dissolvable heart stent for long blockages
This trial tests a new type of stent made from magnesium that slowly dissolves over time. It is for people who have a long blockage in a heart artery that has not been treated before and may be a good option for those who are stable and have not had a recent heart attack.
ErfurtAges 18–80 - NCT03121001RecruitingPhase 2
Transplant from a half-matched donor for aggressive sickle cell
This Phase 2 study tests a “half-matched” stem cell transplant to treat people with aggressive sickle cell disease. It may help by replacing the blood system using stem cells from a related donor who is close but not fully matched.
Chicago, IllinoisAges 16–60 - NCT06719791RecruitingEarly Phase 1
Sirolimus for hard-to-treat focal epilepsy
This trial tests if the drug sirolimus can help people with focal seizures (starting in one part of the brain) that don't improve with at least two other medications. It aims to reduce seizure frequency in adults aged 18 to 60.
BeijingAges 18–60 - NCT06799195RecruitingPhase 2
Better GVHD prevention after stem cell transplant
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
Omaha, NebraskaAges 60 years+ - NCT06872333RecruitingPhase 2
Stem cell transplant from a matched sibling for blood disorders
This trial tests whether a stem cell transplant from a fully matched sibling donor can help people with serious blood disorders like sickle cell disease or thalassemia. It aims to replace the faulty blood system with a healthy one from the donor.
Minneapolis, MinnesotaAges Up to 55 years
Common questions
- Are there clinical trials studying Sirolimus?
- Yes. Clin2 currently lists 104 recruiting studies that include Sirolimus, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Sirolimus trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Sirolimus an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Sirolimus or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.